|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Isella C, Terrasi A, Bellomo SE, Petti C,
Galatola G, Muratore A, Mellano A, Senetta R, Cassenti A, Sonetto
C, et al: Stromal contribution to the colorectal cancer
transcriptome. Nat Genet. 47:312–319. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Giordano G, Febbraro A, Venditti M,
Campidoglio S, Olivieri N, Raieta K, Parcessepe P, Imbriani GC,
Remo A and Pancione M: Targeting angiogenesis and tumor
microenvironment in metastatic colorectal cancer: Role of
aflibercept. Gastroenterol Res Pract. 2014:5261782014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Müeller-Pillasch F, Lacher U, Wallrapp C,
Micha A, Zimmerhackl F, Hameister H, Varga G, Friess H, Büchler M,
Beger HG, et al: Cloning of a gene highly overexpressed in cancer
coding for a novel KH-domain containing protein. Oncogene.
14:2729–2733. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liao B, Hu Y, Herrick D and Brewer G: The
RNA-binding protein IMP-3 is a translational activator of
insulin-like growth factor II leader-3 mRNA during prolifearation
of human K562 leukemia cells. J Biol Chem. 280:18517–18524. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bell JL, Wächter K, Mühleck B, Pazaitis N,
Köhn M, Lederer M and Hüttelmaier S: Insulin-like growth factor 2
mRNA-binding proteins (IGF2BPs): Post-transcriptional drivers of
cancer progression? Cell Mol Life Sci. 70:2657–2675. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gong Y, Woda BA and Jiang Z: Oncofetal
protein IMP3, a new cancer biomarker. Adv Anat Pathol. 21:191–200.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mueller F, Bommer M, Lacher U, Ruhland C,
Stagge V, Adler G, Gress TM and Seufferlein T: KOC is a novel
molecular indicator of malignancy. Br J Cancer. 88:699–701. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yuan RH, Wang CC, Chou CC, Chang KJ, Lee
PH and Jeng YM: Diffuse expression of RNA-binding protein IMP3
predicts high-stage lymph node metastasis and poor prognosis in
colorectal adenocarcinoma. Ann Surg Oncol. 16:1711–1719. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li D, Yan D, Tang H, Zhou C, Fan J, Li S,
Wang X, Xia J, Huang F, Qiu G and Peng Z: IMP3 is a novel
prognostic marker that correlates with colon cancer progression and
pathogenesis. Ann Surg Oncol. 12:3499–3506. 2009. View Article : Google Scholar
|
|
11
|
Lochhead P, Imamura Y, Morikawa T, Kuchiba
A, Yamauchi M, Liao X, Qian ZR, Nishihara R, Wu K, Meyerhardt JA,
et al: Insulin-like growth factor 2 messenger RNA binding protein 3
(IGF2BP3) is a marker of unfavourable prognosis in colorectal
cancer. Eur J Cancer. 48:3405–3413. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin L, Zhang J, Wang Y, Ju W, Ma Y, Li L
and Chen L: Insulin-like growth factor-II mRNA-binding protein 3
predicts a poor prognosis for colorectal adenocarcinoma. Oncol
Lett. 6:740–744. 2013.PubMed/NCBI
|
|
13
|
Herrera M, Islam AB, Herrera A, Martín P,
García V, Silva J, Garcia JM, Salas C, Casal I, de Herreros AG, et
al: Functional heterogeneity of cancer-associated fibroblasts from
human colon tumors shows specific prognostic gene expression
signature. Clin Cancer Res. 19:5914–5926. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fidler IJ: The pathogenesis of cancer
metastasis: The ‘seed and soil’ hypothesis revisited. Nat Rev
Cancer. 3:453–458. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bhowmick NA and Moses HL: Tumor-stroma
interactions. Curr Opin Genet Dev. 15:97–101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang J and Liu J: Tumor stroma as targets
for cancer therapy. Pharmacol Ther. 137:200–215. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Massoner P, Haag P, Seifarth C, Jurgeit A,
Rogatsch H, Doppler W, Bartsch G and Klocker H: Insulin-like growth
factor binding protein-3 (IGFBP-3) in the prostate and in prostate
cancer: Local production, distribution and secretion pattern
indicate a role in stromal-epithelial interaction. Prostate.
68:1165–1178. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Prall F: Tumour budding in colorectal
carcinoma. Histopathology. 50:151–162. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hase K, Shatney CH, Mochizuki H, Johnson
DL, Tamakuma S, Vierra M and Trollope M: Long-term results of
curative resection of ‘minimally invasive’ colorectal cancer. Dis
Colon Rectum. 38:19–26. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bosman FT, Carneiro F, Hruban RH and
Theise ND: WHO classification of tumours of the digestive system,
Fourth Edition. WHO Classif Tumours Digestive System. 3:2010
|
|
22
|
O'Connell JB, Maggard MA and Ko CY: Colon
cancer survival rates with the new American Joint Committee on
Cancer sixth edition staging. J Natl Cancer Inst. 96:1420–1425.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Karamitopoulou E, Zlobec I, Kölzer V,
Kondi-Pafiti A, Patsouris ES, Gennatas K and Lugli A: Proposal for
a 10-high-power-fields scoring method for the assessment of tumor
budding in colorectal cancer. Mod Pathol. 26:295–301. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bissell MJ and Radisky D: Putting tumours
in context. Nat Rev Cancer. 1:46–54. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Calorin L and Bianchini F: Environmental
control of invasiveness and metastatic dissenmination of tumor
cells: The role of tumor cell-host cell interations. Cell Commun
Signal. 8:242010.PubMed/NCBI
|
|
26
|
Sampson N, Zenzmaier C, Heitz M, Hermann
M, Plas E, Schäfer G, Klocker H and Berger P: Stromal insulin-like
growth factor binding protein 3 (IGFBP3) is elevated in the
diseased human prostate and promotes ex vivo
fibroblast-to-myofibroblast differentiation. Endocrinology.
154:2586–2599. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tsujino T, Seshimo I, Yamamoto H, Ngan CY,
Ezumi K, Takemasa I, Ikeda M, Sekimoto M, Matsuura N and Monden M:
Stromal myofibroblasts predict disease recurrence for colorectal
cancer. Clin Cancer Res. 13:2082–2090. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zlobec I and Lugli A: Epithelial
mesenchymal transition and tumor budding in aggressive colorectal
cancer: Tumor budding as oncotarget. Oncotarget. 1:651–661. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Giger OT, Comtesse SC, Lugli A, Zlobec I
and Kurrer MO: Intra-tumoral budding in preoperative biopsy
specimens predicts lymph node and distant metastasis in patients
with colorectal cancer. Mod Pathol. 25:1048–1053. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
van de Velde CJ, Aristei C, Boelens PG,
Beets-Tan RG, Blomqvist L, Borras JM, van den Broek CB, Brown G,
Coebergh JW, Cutsem EV, et al: EURECCA colorectal:
Multidisciplinary mission statement on better care for patients
with colon and rectal cancer in Europe. Eur J Cancer. 49:2784–2790.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ahmed S, Johnson K, Ahmed O and Iqbal N:
Advances in the management of colorectal cancer: From biology to
treatment. Int J Colorectal Dis. 29:1031–1042. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maas M, Nelemans PJ, Valentini V, Das P,
Rödel C, Kuo LJ, Calvo FA, García-Aguilar J, Glynne-Jones R,
Haustermans K, et al: Long-term outcome in patients with a
pathological complete response after chemoradiation for rectal
cancer: A pooled analysis of individual patient data. Lancet Oncol.
11:835–844. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nishio K, Inoue A, Qiao S, Kondo H and
Mimura A: Senescence and cytoskeleton: Overproduction of vimentin
induces senescent-like morphology in human fibroblast. Histochem
Cell Biol. 116:321–327. 2001. View Article : Google Scholar : PubMed/NCBI
|
